Volta Medical has announced the US launch of the AF-Xplorer II system, the company’s next-generation artificial intelligence (AI) solution designed to simplify real-time assessments of complex atrial fibrillation (AF).
A Volta press release states that, building on the success of its predecessor, AF-Xplorer II introduces several key advancements, including:
- High stability analysis, providing physicians with an objective method for identifying regions of interest
- Expanded catheter compatibility, including ability to analyse signals with the Medtronic Sphere-9 mapping and ablation catheter
- Integration with the GE HealthCare CardioLab AltiX AI.i recording system for a more streamlined workflow
These enhancements allow electrophysiologists to deliver more efficient procedures and “focus on what matters most”, Volta also claims.
Earlier this year, AF-Xplorer II received CE-mark approval in Europe and has already been adopted in clinical practice, providing valuable real-world experience that will now extend to US physicians.
“This next-generation technology represents a meaningful step forward in how we approach complex atrial fibrillation, enabling electrophysiologists to perform procedures with greater consistency,” said Devi Nair (St Bernards Heart and Vascular, Jonesboro, USA), who has performed procedures with AF-Xplorer II. “It holds particular promise for the complex atrial fibrillation population, where improving outcomes has historically been a significant challenge.”
“From the beginning, our mission has been to make a real difference in the lives of patients with complex AF, knowing that—despite decades of technical and procedural innovation—efficacy has remained virtually unchanged,” said Théophile Mohr Durdez, chief executive officer (CEO) and co-founder of Volta. “AF-Xplorer II represents a leap forward in both the specificity and interoperability of our algorithm. We can provide more information to physicians to be able to streamline procedures and enhance efficiency, all while maintaining the strong performance Volta Medical demonstrated in the TAILORED-AF trial.”
